Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy product. The study complements an ongoing Phase I/IIA trial for the treatment of delayed-union fractures.
The Phase IIA study will enroll 12 patients with multiple delayed-union fractures of long bones, across 6 sites in Belgium and 4 in Germany. Patients will receive 2 to 4 percutaneous injections of ALLOB at 2, 3 or 4 fracture sites on the same or different bones, evaluating the safety and efficacy of higher ALLOB doses.
ALLOB is in three current Phase I/IIA trials for delayed-union fractures, spinal fusion and the revision of failed spinal fusions.
Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy product. The study complements an ongoing Phase I/IIA trial for the treatment of delayed-union fractures.
The Phase IIA study will enroll 12 patients with multiple delayed-union fractures of long bones,...
Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy product. The study complements an ongoing Phase I/IIA trial for the treatment of delayed-union fractures.
The Phase IIA study will enroll 12 patients with multiple delayed-union fractures of long bones, across 6 sites in Belgium and 4 in Germany. Patients will receive 2 to 4 percutaneous injections of ALLOB at 2, 3 or 4 fracture sites on the same or different bones, evaluating the safety and efficacy of higher ALLOB doses.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
